Hepatitis C virus distribution and clearance following interferon‐monotherapy among thalassaemia major and intermedia patients

A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis

“…Previously, the antifibrotic strategies focused on eradicating causative factors, e.g., viruses. 63 Researchers have recently focused on developing cost-effective small molecules to prevent or reverse liver fibrosis. 64 To enhance the pharmacological actions of small molecules in liver fibrosis therapy and minimize the side effects on non-target tissue or cells, it is essential to develop a targeted drug delivery system that guarantees the delivery of drugs to specific cells or receptors.…”

HCV Infection in Thalassemia Syndromes and Hemoglobinopathies: New Perspectives

“…The treatment of chronic HCV infection began with the administration of interferon (INF) mono therapy, and until a few years ago the recommended therapy available for HCV treatment was pegylated-interferon (PEG-IFN) alpha, plus ribavirin (RBV) with an administration of about 24 weeks (genotypes 2-3) or 48 weeks (genotype 1) (Reddy et al, 2001;Li et al, 2002;Inati et al, 2005;Ricchi et al, 2011;Aminizadeh et al, 2016;Risoluti et al, 2016aRisoluti et al, ,b, 2017Risoluti et al, , 2018Catauro et al, 2018). This treatment produced important side effects, such as irritation at the injection site, febrile influenza-like manifestations, mental disorders, thyropathy, neutropenia, and hemolytic anemia.…”

<p>Thalassemia and hepatocellular carcinoma: links and risks</p>

“…Older regimens for the treatment of HCV infection, based on interferon alone or in combination with ribavirin, achieved limited response rates (sustained virological response (SVR) rates of 25-64% in thalassemia) and were associated with morbidity, adverse drug-drug interactions and hemolysis with consequent iron overload. 3,6,15,73,[106][107][108][109][110][111][112][113][114][115] Therefore, in patients with thalassemia, the 2016 European Association for the Study of the Liver guidelines recommend interferon-free regimens for the treatment of HCV infection. Direct-acting antiviral agents (DAAs) have demonstrated to be safe and effective in patients with chronic HCV infection.…”